Demand for Cosmetic Surgery Procedures Around the World Continues to Skyrocket - USA, Brazil, Japan, Italy and Mexico Ranked in the Top Five Countries
27.6.2017 10:00 | NASDAQ OMX
NEW YORK, June 27, 2017 (GLOBE NEWSWIRE) -- The International Society of Aesthetic Plastic Surgery (ISAPS) today released the results of their annual Global Aesthetic Survey for procedures completed in 2016, which showed an overall increase of 9% in surgical and non-surgical cosmetic procedures within the past twelve months.
Ranking of the World's Top Ten Countries for Cosmetic Procedures
The top five countries - USA, Brazil, Japan, Italy and Mexico - account for 41.4% of the world's cosmetic procedures, followed by Russia, India, Turkey, Germany and France.
% of World-Wide
|13||Chinese Taipei||387,815||1.6 %|
|24||South Africa||45,413||0.2 %|
The Fastest Growing Cosmetic Procedures
In 2016, Labiaplasty showed the largest increase in number of procedures from 2015, with a 45% rise, followed by the Lower Body lift which increased by 29%, the Upper Body Lift and Breast Augmentation using Fat Transfer both demonstrating equal growth at 22%, and the Buttock Lift increasing by 20%.
The Most Popular Cosmetic Surgical Procedures
Breast Augmentation continued to be the world's most popular cosmetic procedure, accounting for 15.8% of all surgical procedures, followed by Liposuction (14%), Eyelid Surgery (12.9%), Rhinoplasty (7.6%) and Abdominoplasty (7.4%). The least popular cosmetic surgery in 2016 was penile enlargement, which also saw the largest decrease in number of procedures (-28%).
The most popular non-surgical procedures continue to be injectables with Botulinum Toxin ranking at number one at 4,627,752 procedures (a 7% increase over the past 12 months).
The Gender Difference
Women continue to drive the demand for cosmetic procedures, accounting for 86.2%, or 20,362,655 cosmetic procedures worldwide. The five most popular procedures requested by women are Breast Augmentation (Silicone Implant), Liposuction, Eyelid Surgery, Abdominoplasty and Breast Lift.
In 2016, men accounted for 13.8% of cosmetic patients with 3,264,254 procedures performed worldwide. Their top five cosmetic procedures requested by men are Eyelid Surgery, Gynecomastia, Rhinoplasty, Liposuction and Hair Transplant.
President of ISAPS, Dr. Renato Saltz, comments, "These results confirm something that most board-certified plastic surgeons already knew - that the demand for cosmetic procedures is stronger than ever. Around the world, we are seeing record numbers of patients looking to take advantage of the latest innovations in cosmetic surgery to look and feel better about themselves."
The data on aesthetic/cosmetic surgical and non-surgical procedures performed in 2016 was tabulated with a questionnaire sent to approximately 35,000 plastic surgeons in ISAPS' proprietary database. ISAPS is the only organization that collects this type of cosmetic data annually on a global scale. The results were compiled, tabulated and analyzed by Industry Insights, an independent research firm based in Columbus, Ohio. For a copy of full results, please visit www.ISAPS.org.
The International Society of Aesthetic Plastic Surgery is the premier global organization for board-certified plastic surgeons. Regarded as the leading global authority on aesthetics and cosmetic surgery, ISAPS has over 3,200 members in 104 countries. Through its rigorous membership requirements, ISAPS plastic surgeons are considered to be among the most qualified in their respective countries, making it easy for patients who are considering cosmetic surgery to start their journey by meeting with an ISAPS plastic surgeon. A full list of ISAPS plastic surgeons can be found at www.ISAPS.org.
Media Contact: Julie Guest, ISAPS Chief Marketing Officer marketing@ISAPS.org 1-844-867-3621
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ISAPS via Globenewswire
Om NASDAQ OMX
NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra NASDAQ OMX
Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra NASDAQ OMX
Vistajet Launches New Digital Platforms as Growth Accelerates in China27.7.2017 14:36 | Pressemelding
VistaJet grows team and launches Chinese website owing to passenger demand VistaJet VistaJet Challenger 850 VistaJet Ltd For the six months to 30th June 2017: Program Membership sales increase globally by a record 57% as customer retention hits 91% across all regions 12% year-on-year increase on passenger departures from China 100% customer renewal rate in Greater China in the first half of 2017 VistaJet Chinese website launched at www.vistajet.cn HONG KONG, July 27, 2017 (GLOBE NEWSWIRE) -- VistaJet continues to build on its China growth and demonstrates a commitment to the region by expanding its team and launching
Minerva Neurosciences to Report Second Quarter 2017 Financial Results and Business Updates on August 3, 201727.7.2017 14:30 | Pressemelding
Management to host conference call WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the second quarter of 2017 on Thursday, August 3, 2017. The Company will host a webcast and conference call that day at 8:30 a.m. Eastern Time to discuss these results and updates. The live call may be accessed by dialing (877) 312-5845 for domestic callers or (765) 507-2618 for international callers and referring to conference ID number 53086270. A live webcast of the conference call will be available online in the Investors and Media section of the Company's website at ir.minervaneurosciences.com. The archived webcast will be available on the Company's website beginning approximately two hours after
Vertiv Sells ASCO® to Schneider Electric27.7.2017 14:22 | Pressemelding
Sale enables greater focus on core business COLUMBUS, Ohio, July 27, 2017 (GLOBE NEWSWIRE) -- Vertiv, formerly Emerson Network Power, today announced plans to sell its ASCO® business as it continues to sharpen its focus on the digital critical infrastructure space. The $1.25 billion sale to Schneider Electric allows Vertiv to apply additional resources toward business and technological advancements in its core data center, telecommunications and commercial and industrial markets. As Vertiv has repositioned itself after being sold to Platinum Equity in November 2016, it became clear that ASCO's strengths in the automatic transfer switch arena fell outside the new organization's more focused strategy, said Vertiv CEO Rob Johnson. "This sale is a significant step forward in our evolution as the premier provider of digital critical infrastructure solutions," Johnson said. "This is consistent with our strategy of focus
Abiomed Announces Q1 FY 2018 Revenue of $132.5 Million, Up 29% Over Prior Year27.7.2017 13:00 | Pressemelding
Company announces Japanese reimbursement for Impella® heart pumps and raises lower end of FY 2018 revenue guidance DANVERS, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today reported first quarter fiscal 2018 revenue of $132.5 million, an increase of 29% compared to revenue of $103.0 million for the same period of fiscal 2017. First quarter fiscal 2018 GAAP net income was $37.4 million or $0.82 per diluted share, compared to GAAP net income of $12.9 million or $0.29 per diluted share for the prior year period. Financial and operating highlights during the first quarter of fiscal 2018 include: Fiscal first quarter worldwide revenue from Impella® heart pumps totaled $127.2 million, an increase of 30% compared to revenue of $97.8 million during the same period of the prior fiscal year. U.S. revenue from Impella heart pumps grew 28% to $114.7 million and
TESARO and Takeda Enter Into Exclusive Licensing Agreement to Develop and Commercialize Novel Cancer Therapy Niraparib in Japan27.7.2017 13:00 | Pressemelding
- Takeda's Rights Include all Potential Indications for Niraparib in Japan and Rights Excluding Prostate Cancer in South Korea, Taiwan, Russia and Australia - TESARO to Receive $100 Million Upfront Payment and is Eligible for Future Regulatory and Commercial Milestones, Plus Royalties WALTHAM, Mass. and OSAKA, Japan, July 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) and Takeda Pharmaceutical Company Limited (TSE:4502) today announced an exclusive licensing agreement for the commercialization and clinical development of niraparib, a novel poly ADP-ribose polymerase (PARP) inhibitor. This agreement includes the development of niraparib for the treatment of all tumor types in Japan, and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia. Niraparib, first marketed in the U.S. in April under the brand name ZEJULA(TM), has quickly
Concurrent Introduces Media Delivery Springboard26.7.2017 17:34 | Pressemelding
Fully Featured Entry Level Video-on-Demand and Live-Streaming Solutions for Cable Operators ATLANTA, July 26, 2017 (GLOBE NEWSWIRE) -- Concurrent (NASDAQ:CCUR), a global leader in storage, protection, transformation and delivery of visual assets, introduces today its new Media Delivery Springboard solutions, a cost-effective means for small and medium-sized independent cable operators to ingest, store, transform and deliver video-on-demand (VOD) and live-streaming content. Traditional content delivery networks come with high start-up costs, which present a challenge for small and mid-size operators that may lack the necessary capital to invest in large-scale infrastructure. Concurrent's new Media Delivery Springboard helps independent cable operators with smaller budgets and limited resources remain competitive with an entry-level video delivery solution requiring minimal infrastructure investment. There are three options available, including a VOD solution fo
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom